RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.
How this was made
The 30-second read
Why it matters
The enrollment milestone de‑risks the TAMP platform and could improve market perception, but immediate price impact is likely modest until efficacy data emerge.
Market read
Primary biotech news; relevant for investors tracking early‑stage oncology device companies.
What to watch
Potential competition from other intra‑arterial delivery platforms and the need for FDA approval of the combination product.
Background
RenovoRx (NASDAQ: RNXT) announced the first patient enrollment in its PRISM‑TAMP trial, an IIT evaluating gemcitabine delivered via its FDA‑cleared RenovoCath device for borderline resectable pancreatic cancer.
Ticker impact
First patient enrolled in the PRISM-TAMP investigator‑initiated trial for borderline resectable pancreatic cancer.
modest upside as investors price in progress toward data readout.
Early‑stage trial start is a concrete milestone; no revenue impact yet but de‑risking is valued.
Market effects
May boost broader oncology device/targeted‑delivery sector as proof‑of‑concept advances.
Limited to U.S. biotech investors; no broader regional effect.
Low global relevance beyond niche biotech community.
Counterpoint
Trial enrollment does not guarantee success; investors may wait for efficacy data before acting.
Key entities
- companyRenovoRx, Inc.
Life‑sciences firm developing the TAMP platform and RenovoCath device.
- institutionUniversity of Vermont (UVM)
Sponsor of the investigator‑initiated PRISM‑TAMP trial.
